Citations

Showing 10 of 108083 citations.

Reticular Hyperpigmented Eruption in a Young Woman
Hoesly, Paul M. , Cappel, Mark A.

Mayo Clinic

JAMA Dermatology | November 22, 2017 | Volume: 154 | Issue: 3 | Pages: 353

10.1001/jamadermatol.2017.4693 | PMID 29167869 Get It

Factors Associated With Failure of Adult Strabismus–20 Questionnaire Scores to Improve Following Strabismus Surgery
Leske, David A. , Philbrick, Kemuel L. , Holmes, Jonathan M. , Hatt, Sarah R. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | November 22, 2017 | Volume: 136 | Issue: 1 | Pages: 46

10.1001/jamaophthalmol.2017.5088 | PMID 29167898 Get It

Treatment of severe drug reactions by hemodialysis
Wang, Michael Z. , Wentworth, Ashley B., Hickson, LaTonya J. , El-Azhary, Rokea A, Hickson, LaTonya J , el‐Azhary, Rokea A.

Mayo Clinic

International Journal of Dermatology | November 22, 2017 | Volume: 57 | Issue: 2 | Pages: 177-182

10.1111/ijd.13837 | PMID 29165802 Get It

AbstractBackgroundExtracorporeal treatments such as hemodialysis and plasma exchange are lifesaving measures in the treatment of drug poisoning. This treatment method generally is not used for severe cutaneous and systemic drug reactions.MethodsHere, we describe three cases wherein hemodialysis therapy was instrumental in reversing the adverse drug reaction.ResultsIn the cases of severe cutaneous drug reactions reviewed, patients presented with linear immunoglobulin A bullous dermatosis, acute generalized exanthematous pustulosis, and toxic epidermal necrolysis. Salvage treatment with hemodialysis therapy drastically influenced the course of disease, resulting in remission.ConclusionsThis novel and highly effective treatment option is not considered in current algorithms for adverse drug reactions. Hence, in addition to the rarity of these reactions, the main limitation of the study is the small number of patients. Hemodialysis can substantially alter the prognosis and, in some cases, be a lifesaving treatment for patients with severe adverse cutaneous drug reaction associated with systemic toxicity.
Discordance of pediatric morphea treatment by pediatric dermatologists
Tollefson, Megha M. , Chiu, Yvonne E. , Brandling‐Bennett, Heather A. , Pope, Elena , Chiu, Yvonne E

Mayo Clinic

Pediatric Dermatology | November 22, 2017 | Volume: 35 | Issue: 1 | Pages: 47-54

10.1111/pde.13281 | PMID 29165838 Get It

AbstractBackground/ObjectivesStudies describing treatment efficacy in pediatric morphea are lacking. Subspecialists have reached no consensus on how to optimally treat pediatric morphea. The objective of the current study was to describe the most common treatment practices of pediatric dermatologists worldwide who care for children with morphea.MethodsA survey regarding topical treatment practices of pediatric morphea, with representative case‐based scenarios, was distributed to pediatric dermatologists and results were tallied.ResultsThe survey response rate was 13.4%, with 110 respondents in the final analysis. The majority of respondents agreed on red violaceous rim (99%), increased local warmth (75%), raised borders (69%), and dermal thickening (64%) as signs of disease activity. Respondents had less agreement on sclerotic lesions (41%), scaling (43%), dyspigmentation (19%), and atrophy (13%) as signs of disease activity. Ninety‐two percent of respondents used primary therapy or monotherapy with topical medications, including 45% in linear morphea of the limbs and 37% in linear morphea of the head or neck. High‐potency topical corticosteroids were most commonly used (80%), although respondents did not agree on specific regimens. Sixteen different treatment regimens were selected as first‐line therapy for one case scenario of active disease.ConclusionThe survey found large variation in how pediatric dermatologists treat pediatric morphea. Consensus treatment guidelines developed by pediatric dermatologists and pediatric rheumatologists are urgently needed regarding the efficacy of therapies for pediatric morphea. Prospective studies of treatment efficacy in pediatric morphea are urgently needed as well.
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
Walter, Roland B. , Michaelis, Laura C. , Uy, Geoffrey L. , Radich, Jerald P. , Little, Richard F. , Hita, Sandi, Saini, Lalit , Foran, James M. , Gerds, Aaron T. , Couban, Stephen, Litzow, Mark R. , Stone, Richard M. , Little, Richard F , Gerds, Aaron T , Lancet, Jeffrey E , Walter, Roland B , Othus, Megan , Klepin, Heidi D. , Hay, Annette E. , Assouline, Sarit E. , Lancet, Jeffrey E. , Erba, Harry Paul , Uy, Geoffrey

Mayo Clinic

American Journal of Hematology | November 22, 2017 | Volume: 93 | Issue: 2 | Pages: No page available

10.1002/ajh.24980 | PMID 29164656 Get It

Subscapularis Tenotomy in Anatomic Total Shoulder Arthroplasty
Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Shoulder and Elbow Arthroplasty | November 22, 2017 | Volume: 1 | Issue: No issue available | Pages: No page available

10.1177/2471549217743605 Get It

Tenotomy of the subscapularis is commonly used for exposure at the time of anatomic total shoulder arthroplasty. Understanding the anatomy of the subscapularis and its footprint for insertion into the lesser tuberosity helps perform an adequate tenotomy. Incision of the tendon at the right level, release of the anterior capsule to restore excursion, a sound repair, and postoperative protection are important. Controversy remains regarding the relative advantages and disadvantages of tenotomy compared with alternatives, in particular osteotomy of the lesser tuberosity. Tenotomy has been associated with a higher rate of positive physical examination findings for subscapularis weakness and concerning tendon attenuation or rupture in some shoulders evaluated with ultrasound. However, patient-reported outcomes, objective measurement of strength in internal rotation, and revision and reoperation rates are identical with tenotomy and osteotomy. Tenotomy is particularly attractive in terms of simplicity, shorter operative time, and use in stemless shoulder arthroplasty. Failure of the tenotomy to heal leading to anterior instability can be salvaged surgically, but oftentimes requires revision to a reverse arthroplasty.
Effect of early hospital readmission and comorbid conditions on subsequent long‐term mortality after transient ischemic attack
Yousufuddin, Mohammed , Keenan, Lawrence R., Olson, Tammy, Shultz, Jessica, Doyle, Taylor, Ahmmad, Eimad M. , Arumaithurai, Kogulavadanan , Takahashi, Paul Y. , Murad, M. Hassan , Young, Nathan, Keenan, Lawrence, Ahmmad, Eimad, Takahashi, Paul, Murad, Mohammad Hassan, Murad, M Hassan , Takahashi, Paul , Young, Nathan P.

Mayo Clinic

Brain and Behavior | November 22, 2017 | Volume: 7 | Issue: 12 | Pages: No page available

10.1002/brb3.865 | PMID 29299384 Get It

AbstractBackgroundThe implications of early readmission on long‐term mortality after transient ischemic attack (TIA) are not known. We aimed at examining the effect of 180‐day readmission on subsequent long‐term mortality after index hospitalization for TIA.MethodsA retrospective study of patients hospitalized for first‐ever TIA at Mayo Clinic from 2000 through 2017. Patients readmitted within 180 days postdischarge were compared with those not readmitted in long‐term risk of death.ResultsOf 251 TIA patients aged 73 ± 15 years with 1509 person‐years of follow‐up, 65 (26%) were readmitted within 180 days of discharge and 125 died during a median follow‐up of 5.7 years. The mortality was 10 vs. 7 deaths per 100 person‐years in patients who were readmitted compared to those who were not readmitted with hazard ratio (HR) 1.73 (95% confidence interval [CI] 1.13–2.66). Other competing predictors of mortality were age ≥65 years (HR 5.70, 95% CI 2.72–11.96), cancer (HR 1.65, 95% CI 1.03–3.38), chronic obstructive pulmonary disease (HR 1.90, 95% CI 1.07–3.38), heart failure (HR 3.03, 95% CI 1.82–5.06), dementia (HR 5.87, 95% CI 3.27–10.52), creatinine ≥1.4 mg/dl (HR 1.89, 95% CI 1.17–3.06), and hemoglobin level <10 g/dl (HR 2.80, 95% CI 1.20–6.66).ConclusionsHospital readmission within 180 days of discharge from index TIA was associated with increased risk of death several years after initial readmission. Older age and several comorbidities identified during index hospitalization also confer increased risk for long‐term mortality.
Driver mutations and prognosis in primary myelofibrosis: Mayo‐Careggi MPN alliance study of 1,095 patients
Tefferi, Ayalew , Nicolosi, Maura , Mudireddy, Mythri , Finke, Christy M. , Hanson, Curtis A. , Pardanani, Animesh , Gangat, Naseema , Mannarelli, Carmela, Fanelli, Tiziana , Szuber, Natasha , Lasho, Terra L. , Gangat, Naseema , Vannucchi, Alessandro M , Ketterling, Rhett P. , Guglielmelli, Paola , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | November 22, 2017 | Volume: 93 | Issue: 3 | Pages: 348-355

10.1002/ajh.24978 | PMID 29164670 Get It

Abstract The 2013 discovery of calreticulin ( CALR ) mutations in myeloproliferative neoplasms was attended by their association with longer survival in primary myelofibrosis (PMF). Subsequent studies have suggested prognostic distinction between type 1/like and type 2/like CALR mutations and detrimental effect from triple‐negative mutational status. Among 709 Mayo Clinic patients with PMF, 467 (66%) harbored JAK2 , 112 (16%) CALR type 1/like, 24 (3.4%) CALR type 2/like, 38 (5.4%) MPL mutations and 68 (10%) were triple‐negative. Survival was longer with type 1/like CALR , compared to JAK2 (HR 2.6, 95% CI 1.9‐3.5), type 2/like CALR (HR 2.5, 95% CI 1.4‐4.5), MPL (HR 1.8, 95% CI 1.1‐2.9) and triple‐negative mutational status (HR 2.4, 95% CI 1.6‐3.6), but otherwise similar between the non‐type 1/like CALR mutational states ( P = .41). In multivariable analysis, the absence of type 1/like CALR ( P < .001; HR 2, 95% CI 1.4‐2.7), presence of ASXL1 / SRSF2 mutations ( P < .001; HR 1.9, 95% CI 1.5‐2.4) and DIPSS‐plus ( P < .001) were each predictive of inferior survival. Furthermore, among 210 patients with ASXL1 / SRSF2 mutations, survival was significantly longer in the presence vs. absence of type 1/like CALR mutations (median 5.8 vs. 2.9 years; P < .001). Triple‐negative status did not disclose additional prognostic information for overall or leukemia‐free survival. The observations regarding the prognostic distinction between CALR mutation variants were validated in an external cohort of 386 patients from the University of Florence Careggi hospital. We conclude that type 1/like CALR mutations in PMF not only predict superior survival, but also partially amend the detrimental effect of high molecular risk mutations.
Modern Fixed Imaging Systems Reduce Radiation Exposure to Patients and Providers
Stangenberg, Lars , Shuja, Fahad , Bom, I.M.J. van der , Alfen, Martine H. G. van, Hamdan, Allen D., Wyers, Mark C. , Guzman, Raul J. , Schermerhorn, Marc L. , Alfen, Martine van

Mayo Clinic

Vascular and Endovascular Surgery | November 21, 2017 | Volume: 52 | Issue: 1 | Pages: 52-58

10.1177/1538574417742211 | PMID 29162024 Get It

High-definition fluoroscopic imaging is required to perform endovascular procedures safely and precisely, especially in complex cases, resulting in longer procedures and increased radiation exposure. This is of importance for training institutions as trainees, even with sound instruction in as low as reasonably achievable (ALARA) principles, tend to have high radiation exposures. Recently, there was an upgrade in the imaging system allowing for comparison of radiation exposure to patients and providers. We performed an analysis of consecutive endovascular aneurysm repair (EVAR) and superficial femoral artery (SFA) interventions in the years 2013 to 2014. We recorded body mass index (BMI) and fluoroscopy time (FT) and subsequently matched 1:1 based on BMI, FT, or both. We determined radiation dose using air kerma (AK) and also recorded individual surgeons’ badge readings. Allura Xper FD20 was upgraded to AlluraClarity with ClarityIQ. We identified a total of 77 EVARs (52 pre and 25 post) and 134 SFA interventions (99 pre and 35 post). Unmatched results for EVAR were BMI pre 26.2 versus post 25.8 (kg/m 2 , P = .325), FT 28.1 versus 21.2 (minutes, P = .051), and AK 1178.5 versus 581 (mGy, P < .001), respectively. After matching, there was a 53.2% reduction in AK (846.1 vs 395.9 mGy; P = .004) for EVAR. Unmatched results for SFA interventions were BMI pre 28.1 versus post 26.6 ( P = .327), FT 18.7 versus 16.2 ( P = .282), and AK 285.6 versus 106.0 ( P < .001), respectively. After matching, there was a 57.0% reduction in AK (305.0 vs 131.3, P < .001). The total deep dose equivalent from surgeons’ badge readings decreased from 39.5 to 17 mrem ( P = .029). Aortic and peripheral endovascular interventions can be performed with reduced radiation exposure to patients and providers, employing modern fixed imaging systems with advanced dose reduction technology. This is of particular importance in the light of the increasing volume and complexity of endovascular and hybrid procedures as well as the prospect of decades of radiation exposure during training and practice.